CardioDx CEO and leadership

Khush Mehta is a Chairman at Arterys and Board Member at CardioDx Inc and is based in San Francisco Bay Area. He has worked as Chief Strategy Officer at Siemens Healthineers, Chief Strategy Officer at Siemens AG Healthcare Sector, and President/CEO at CardioDx Inc. Khush works or has worked as Member and Interviewer at Yale University, Alumni Selection Commitee (ASC) and Chief Strategy Officer at SIEMENS HEALTH-CARE LTD. He attended Sydenham College of Commerce and Economics, The Institute of Chartered Accountants of India, and Yale between 1990 and 1992.

David founded CardioDx in 2004, and served as the President and Chief Executive Officer of the company until 2016. David drove the successful commercialization of the Corus CAD blood test with over 250,000 patients having received and benefited from the Corus CAD test. Prior to launching CardioDx, David was a Venture Partner at Texas Pacific Group Ventures and was also the interim Chief Executive Officer and Director of CareDx (formerly XDx, Inc.). Previously, he was the Founder, President, and Chief Executive Officer of iScribe, a healthcare technology company acquired by AdvancePCS (now Caremark). Prior to iScribe, David was President of Oncology Therapeutics Network (OTN), which was acquired by Bristol-Myers Squibb in 1996. Prior to OTN, he was with Cole Gilburne Fund, an early-stage, technology-focused venture capital firm. David continues to serve as a Director on both public and private Boards.

Dr. Mark Monane is a Chief Medical Officer at CardioDx Inc and is based in United States.

David founded CardioDx in 2004, and served as the President and Chief Executive Officer of the company until 2016. David drove the successful commercialization of the Corus CAD blood test with over 250,000 patients having received and benefited from the Corus CAD test. Prior to launching CardioDx, David was a Venture Partner at Texas Pacific Group Ventures and was also the interim Chief Executive Officer and Director of CareDx (formerly XDx, Inc.). Previously, he was the Founder, President, and Chief Executive Officer of iScribe, a healthcare technology company acquired by AdvancePCS (now Caremark). Prior to iScribe, David was President of Oncology Therapeutics Network (OTN), which was acquired by Bristol-Myers Squibb in 1996. Prior to OTN, he was with Cole Gilburne Fund, an early-stage, technology-focused venture capital firm. David continues to serve as a Director on both public and private Boards.